What exactly changed in the Raymond James note on REGN?

On January 30, 2026 Raymond James maintained an Outperform rating on REGN and raised the price target to $870 from $820, reflecting improved model assumptions while keeping the same positive stance.

How should investors use the REGN analyst rating in decisions?

Use the REGN analyst rating as one input: weigh the maintained Outperform and $870 target against your risk tolerance, pipeline timelines, and position sizing before making trade decisions.

Does the higher price target mean a guaranteed upside for REGN?

No. A higher REGN analyst rating price target reflects analyst expectations, not guarantees; outcomes still depend on clinical data, sales trends, and market conditions.

Where can I find the Raymond James note and broader analyst updates?

The Raymond James update is summarized by TheFly and aggregated analyst coverage is available on Investing.com for broader context on REGN analyst rating activity.

Analyst Ratings

Raymond James Maintains Outperform for Regeneron (REGN) Jan 30, 2026

ByHuzaifa Zahoor February 2, 2026February 2, 2026

Raymond James on January 30, 2026 maintained an Outperform rating for Regeneron Pharmaceuticals, Inc. (REGN) and raised its price target to $870 from $820. This action is a retention of positive conviction rather than a formal upgrade, and it signals continued analyst confidence in Regeneron’s drug portfolio and cash flow. The update is recorded by TheFly and shows minimal immediate market movement, with a reported intraday change of -0.01% (-$0.08). Investors watching REGN analyst rating shifts should note the price target lift and what it implies for valuation and downside protection.